Recent Deals Signal a Continued Shift in the Innovative Pharmaceutical Business Model

In the past few months, there have been a number of significant transactions between innovative and generic drug companies, including deals between GlaxoSmithKline Inc and Aspen Pharmacare Holdings Limited, and between Daiichi Sankyo Company, Limited and Ranbaxy Laboratories Limited. This development seems to be part of a shift away from the traditional "blockbuster drug" business model of large innovative pharmaceutical companies and an increasing interest in emerging markets, particularly those of Asia. A more detailed discussion of these recent deals can be found by following this link. Summary by: Michael Migus